Biomarin Pharmaceutical Inc

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $12.71B
  • PE 39
  • Debt $600.00M
  • Cash $675.45M
  • EV $12.63B
  • FCF $319.89M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$322.29M
EBIT$391.45M
ROE6%
ROA6%
FCF$319.89M
Equity$5.41B
Growth Stability-25%
PE39.43
PEG-3.59
PB2.35
P/FCF39.72
P/S4.62
Price/Cash0.05
Debt/Equity0.11
Debt/FCF1.88
Net Margins14%
Gross Margins79%
Op. Margins14%
Earnings CAGR-2%
Sales Growth YoY28%
Sales Growth QoQ5%
Sales CAGR12%
FCF CAGR2%
Equity CAGR11%
Earnings Stability0
Earnings Growth YoY163%
Earnings Growth QoQ-1%
Earnings CAGR 5Y-11%
Sales CAGR 5Y9%
FCF CAGR 5Y20%
Equity CAGR 5Y10%
Earnings CAGR 3Y16%
Sales CAGR 3Y16%
FCF CAGR 3Y63%
Equity CAGR 3Y8%
Market Cap$12.71B
Revenue$2.75B
Assets$6.85B
Total Debt$600.00M
Cash$675.45M
Shares Outstanding189.81M
EV12.63B
Earnings Score6%
Moat Score78%
Safety Score64%
Final Score50%
Working Capital2.34B
Current Ratio4.27
Shares Growth 3y1%
Equity Growth QoQ2%
Equity Growth YoY11%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.

SEC Filings

Direct access to Biomarin Pharmaceutical Inc (BMRN) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Biomarin Pharmaceutical Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Biomarin Pharmaceutical Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -2%
Stability 0%
loading chart...

Biomarin Pharmaceutical Inc Discounted Cash Flow

Fully customizable DCF calculator online for Biomarin Pharmaceutical Inc.

= $3.6B
012345678910TV
fcf$320M$325M$330M$335M$340M$346M$351M$357M$362M$368M$374M$3.7B
DCF$295M$273M$252M$233M$215M$198M$183M$169M$156M$144M$1.4B
Value$3.6B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-18%-19%-56%-9%-5%-1%46%-3%7%7%14%
ROA--3%-20%0%-2%-2%-0%-1%2%3%6%
ROE--7%-23%-4%-3%-1%21%-2%3%3%6%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF--1.47-1.82-5.65-6.99-12.73-385.2620.0225.471.88
Debt over Equity0.430.280.250.420.290.390.270.260.240.320.11
Growth Stability--------25%55%54%-25%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-18%26%18%14%14%9%-1%14%15%9%
Earnings YoY growth-28%267%-81%-34%-69%-4K%-107%-321%18%-11%
Equity YoY growth-57%15%2%6%5%32%4%8%8%10%
FCF YoY growth-134%-16%-45%-40%-22%-70%-822%-74%14%20%